Monogenic inflammatory bowel disease
Determining a definitive diagnosis
Unlike patients with polygenic inflammatory bowel disease (IBD), most patients with monogenic IBD show symptoms before age 6. Because monogenic and polygenic IBD can have indistinguishable endoscopic or histologic features, establishing accurate diagnosis via traditional methods remains a challenge.1
Monogenic IBD Test menu
Monogenic IBD
Genetic testing can identify patients with monogenic IBD and primary immunodeficiencies that present with IBD-like features. Isolating the genetic cause of the illness enables clinicians to choose treatment options that enhance outcomes. Our comprehensive monogenic IBD panel detects variants in 107 genes with established associations to monogenic IBD and primary immunodeficiencies that present with IBD-like features but do not respond to standard IBD treatments. This includes testing for genes associated with rare diseases, such as Mediterranean Fever, with increased prevalence in certain ancestral groups.
Key testing
Advantages
- Helpful for children with early-onset IBD, which typically occurs in children under age 6.
- Identifies genetic variants in 107 genes with known associations to IBD and immunodeficiency.
- Can help establish diagnosis and, in some cases, support appropriate management and surveillance for disease features based on the involved gene.
- Includes testing for genes associated with rare diseases, such as Mediterranean fever, that are more prevalent in certain ancestral groups.
- Test results are interpreted by a team of experienced laboratory directors and genetic counselors who classify variants detected using American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines.
- Includes detailed reports that contextualize findings to provide clarity on disease presence, providing ordering physicians the autonomy to make a diagnosis based on patient-specific factors.
Highlights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy for patients, who might be as young as 2 years of age.
Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic, in this “Specialty Testing” webinar, for a discussion of this testing and its clinical application.
References
- Lega S, Pin A, Arrigo S, Cifaldi C, Girardelli M, et al. Diagnostic approach to monogenic inflammatory bowel disease in clinical practice: a ten-year multicentric experience. Inflamm Bowel Dis. 2019;20(20):1-8.